Wet Macular Degeneration: Diagnosis, Monitoring, and Anti-VEGF Treatment

Changes in central vision can happen gradually in some eye conditions, but in wet age-related macular degeneration they may develop over days or weeks. This form of the disease involves abnormal blood vessels growing under the macula, the part of the retina responsible for detailed sight. Because those vessels can leak fluid or blood, prompt diagnosis and steady follow-up are central to protecting as much vision as possible.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Wet macular degeneration symptoms

Recognizing wet macular degeneration symptoms early can make a meaningful difference in care. Common signs include blurred central vision, straight lines that begin to look wavy, a dark or empty spot in the center of sight, reduced ability to read, and trouble recognizing faces. Some people also notice that colors seem less vivid. These changes usually affect fine-detail tasks first rather than side vision. Any sudden distortion or unexplained drop in central vision should be assessed quickly, because wet disease can progress faster than the more gradual dry form.

How diagnosis is confirmed

Diagnosis usually starts with a dilated eye exam and a discussion of recent vision changes. Eye care professionals often use optical coherence tomography, or OCT, to create detailed cross-sectional images of the retina and look for swelling or fluid. Fluorescein angiography may also be used to highlight leaking blood vessels after a dye is injected into a vein. Visual acuity testing and an Amsler grid can help document how central vision is being affected. Together, these tools help distinguish wet disease from other retinal problems and guide treatment planning.

Anti-VEGF injection treatment

Anti-VEGF injection treatment is the standard approach for many patients with wet age-related macular degeneration. VEGF, or vascular endothelial growth factor, is a protein that can promote the growth and leakage of abnormal blood vessels. Medications injected into the eye are designed to block that activity and reduce fluid buildup. Treatment is typically given in a specialist setting after the eye is numbed, and the procedure itself is usually brief. Many patients need a series of injections over time, because the goal is control and stabilization rather than a one-time cure.

Response to treatment varies from person to person. Some patients notice clearer or more stable vision after the first few injections, while others improve more gradually. Retina specialists may use monthly treatment at first, then adjust to a personalized schedule such as treat-and-extend based on exam findings and OCT results. Commonly used medicines include aflibercept, ranibizumab, faricimab, and bevacizumab in appropriate clinical settings. The exact choice depends on medical judgment, disease activity, access, and how the eye responds over time.

Why regular eye monitoring matters

Regular eye monitoring remains important even after treatment begins. Wet disease can reactivate, and fluid may return before a patient notices obvious symptoms. Follow-up visits often include vision testing, dilated examination, and repeat OCT imaging to check whether the retina is dry, stable, or active again. Monitoring schedules are individualized, but consistency matters because missed appointments can delay needed treatment. At home, some patients are advised to use an Amsler grid to watch for new distortion, blank spots, or changes that should be reported promptly.

Vision preservation strategies

Vision preservation strategies involve more than injections alone. Good lighting, magnifying tools, large-print materials, and contrast-enhancing adjustments can make daily tasks easier. Managing cardiovascular risk factors, not smoking, and following general health advice may also support overall eye health. Nutritional supplements are sometimes discussed for certain patients with age-related macular degeneration, although they do not replace treatment for the wet form. It is also helpful to protect the eyes from strain during reading by taking breaks and using prescribed glasses that match current vision needs.

Retinal specialist care

Retinal specialist care is often central to long-term management because these physicians focus on diseases of the retina and have access to imaging and injection-based treatment. Care may involve coordination between an optometrist, a general ophthalmologist, a retina specialist, and a primary care clinician. This team approach can help patients understand what symptoms deserve urgent attention and what level of change is expected between visits. For people in the United States, local services for low-vision rehabilitation may also improve independence when central vision remains limited despite treatment.

Although wet age-related macular degeneration is a serious diagnosis, timely evaluation and structured follow-up have changed its outlook considerably. Early recognition of symptoms, confirmation with retinal imaging, and ongoing anti-VEGF therapy can slow damage and help preserve useful sight. Because the condition can change over time, steady monitoring and individualized specialist care remain essential parts of living with it.